Comparative Pharmacology
Head-to-head clinical analysis: ONGLYZA versus SAXAGLIPTIN METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ONGLYZA versus SAXAGLIPTIN METFORMIN HYDROCHLORIDE.
ONGLYZA vs SAXAGLIPTIN;METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing incretin hormones (GLP-1, GIP) to enhance glucose-dependent insulin secretion and suppress glucagon release.
Saxagliptin inhibits DPP-4, increasing incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and reducing glucagon. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
2.5 mg or 5 mg orally once daily
Each tablet contains saxagliptin 5 mg and metformin hydrochloride 500 mg or 1000 mg. The recommended starting dose is 5 mg saxagliptin and 500 mg metformin hydrochloride orally twice daily; titrate gradually based on efficacy and tolerability. Maximum daily dose: saxagliptin 5 mg, metformin hydrochloride 2000 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 12.4 hours for saxagliptin. The half-life of its active metabolite is about 2.1 hours. The pharmacologically relevant half-life supports once-daily dosing.
Saxagliptin: 2.5 hours (parent), 3.1 hours (active metabolite). Metformin: 6.2 hours (plasma), prolonged in renal impairment.
Approximately 75% of the administered dose is excreted in urine, with about 21% recovered as parent drug, and the remainder as metabolites. Fecal excretion accounts for about 22% of the dose, primarily as parent drug and metabolites.
Saxagliptin: 75% renal (24% unchanged, 51% as metabolite), 22% fecal. Metformin: 90% renal (unchanged).
Category C
Category A/B
DPP-4 Inhibitor
DPP-4 Inhibitor